EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Enhancing Drug Response Prediction in Epilepsy with Emerging Multimodal Models: Focus on Clinical, Pharmacologic, and Genomic Factors

Alison Anderson iD, Richard Shek-Kwan Chang iD, Mark Howard, Zhibin Chen iD, Duong Nhu iD, Zongyuan Ge iD, Patrick Kwan iD

CNS Drugs · 2026-06 · 40 (6) · 743-760

DOI: 10.1007/s40263-026-01295-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift CNS Drugs, online erschienen am 16.05.2026. Verfasst von Alison Anderson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC, 3004, Australia. Hauptthemen laut MEDLINE: Anticonvulsants, Epilepsy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Health and Medical Research Council, Monash University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epilepsy is a common neurological disorder, with approximately one-third of the affected population developing drug-resistant epilepsy despite the exponentially increasing number of antiseizure medications (ASMs) that are available. Current ASM selection remains largely empirical, lacking reliable biomarkers to predict treatment response. Pharmacogenomics is an important factor underlying drug response. The development of models designed to predict drug response in epilepsy that include genomic information is at an early stage. Advances in artificial intelligence (AI) and deep learning (DL) offer new opportunities for multimodality modelling and, in particular, models that can reason over both a patient's genomic risk factors and their clinical features (e.g. epilepsy type, magnetic resonance imaging [MRI]/electroencephalography [EEG] findings). More broadly, new technologies are driving a paradigm shift towards agentic AI, whereby decision-support agents will coordinate medical information and propose actions. These advances have implications for individualised ASM prescribing in epilepsy. For example, rather than modelling thousands of genetic variants, a DL model can operate with compressed representations of data obtained from AI foundation models that have been trained on huge atlases to learn representations of general biology, enhancing capacity for small epilepsy cohorts. In this review, we summarise how emerging technologies are being harnessed and highlight strategies for building capacity. We specifically focus on clinical, pharmacological, and genomic data, discussing the ways in which drug information can be formatted to take advantage of DL model capabilities. We describe AI foundation models and provide examples of how they can be utilised in epilepsy research. We conclude with a summary of ongoing challenges, including model evaluation, data availability, ethical considerations, and barriers to clinical translation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsEpilepsyHumansPharmacogeneticsArtificial IntelligenceGenomicsDeep LearningAnimals

Substanzen

Anticonvulsants

Autor:innen und Institutionen

  • Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC, 3004, Australia.
  • Department of Philosophy, School of Philosophical, Historical, and Indigenous Studies, Faculty of Arts, Monash University, Melbourne, VIC, 3800, Australia.
  • Monash Medical AI, Monash University, Melbourne, VIC, 3800, Australia.
  • Department of Data Science and Artificial Intelligence, Monash University, Melbourne, VIC, 3800, Australia.
  • AIM for Health Lab, Monash University, Melbourne, VIC, 3800, Australia.
  • Department of Electrical and Computer Systems Engineering, Monash University, Melbourne, VIC, 3800, Australia.

ORCID-Profile: Alison Anderson, Richard Shek-Kwan Chang, Zhibin Chen, Duong Nhu, Zongyuan Ge, Patrick Kwan

Förderung

  • National Health and Medical Research Council
  • Monash University

Zitieren

APA

Anderson, A., Chang, R. S., Howard, M., Chen, Z., Nhu, D., Ge, Z., & Kwan, P. (2026). Enhancing Drug Response Prediction in Epilepsy with Emerging Multimodal Models: Focus on Clinical, Pharmacologic, and Genomic Factors. CNS Drugs, 40(6), 743-760. https://doi.org/10.1007/s40263-026-01295-8

Vancouver

Anderson A, Chang RS, Howard M, Chen Z, Nhu D, Ge Z, et al. Enhancing Drug Response Prediction in Epilepsy with Emerging Multimodal Models: Focus on Clinical, Pharmacologic, and Genomic Factors. CNS Drugs. 2026;40(6):743-760. doi:10.1007/s40263-026-01295-8

BibTeX
@article{Anderson2026,
  author = {Anderson, Alison and Chang, Richard Shek-Kwan and Howard, Mark and Chen, Zhibin and Nhu, Duong and Ge, Zongyuan and Kwan, Patrick},
  title = {Enhancing Drug Response Prediction in Epilepsy with Emerging Multimodal Models: Focus on Clinical, Pharmacologic, and Genomic Factors},
  journal = {CNS Drugs},
  year = {2026},
  volume = {40},
  number = {6},
  pages = {743--760},
  doi = {10.1007/s40263-026-01295-8}
}
Kostenlos starten →